Vasospasm after traumatic or aneurysmal subarachnoid hemorrhage is associat
ed with smooth muscle contraction, a process that results in part from incr
eased intracellular calcium in smooth muscle cells. These experiments teste
d the hypothesis that chelation of intracellular calcium with the cell-perm
eant calcium chelator, 1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetracetic
acid acetoxymethyl ester (BAPTA-AM), decreases smooth muscle contraction in
response to agents that cause contraction by increasing intracellular calc
ium. Effects of BAPTA-AM on vasoconstriction induced by KCl, prostaglandin
F-2 alpha (PGF(2 alpha)), caffeine, and erythrocyte hemolysate were tested
on monkey basilar artery under isometric tension. BAPTA-AM, 30 and 100 mu m
ol/L, caused a significant decrease in resting tension in rings with and wi
thout endothelium (30 mu mol/L; 8 +/- 6% [n.s.] and 14 +/- 5%, 100 mu mol/L
; 19 +/- 3% and 32 +/- 6%, p < 0.05, paired t test). Contractions to caffei
ne were significantly decreased by 30 mu mol/L BAPTA-AM and were abolished
at 100 mu mol/L in rings with and without endothelium (p < 0.05). BAPTA-AM,
100 mu mol/L, competitively inhibited contractions to PGF(2 alpha). BAPTA-
AM, 100 mu mol/L, significantly decreased the maximum contractions to KCl i
n rings with and without endothelium (p < 0.05). There were no significant
effects of BAPTA-AM on contractions induced by hemolysate in rings with end
othelium but in rings without endothelium, BAPTA-AM, 100 mu mol/L, signific
antly inhibited contractions. In rings with endothelium contractions to hem
olysate could be significantly reduced by BAPTA-AM plus indomethacin or ind
omethacin alone, suggesting that hemolysate releases an eicosanoid from the
endothelium by a pathway that is not inhibited by BAPTA. These results sug
gest that the ability of BAPTA-AM to inhibit smooth muscle contractions wil
l depend on the agonists mediating the contraction. In response to erythroc
yte hemolysate, loading of endothelial cells with BAPTA-AM increases the re
lease of a vasoconstricting eicosanoid from these cells that counteracts th
e decreased contraction caused by loading of smooth muscle cells with BAPTA
-AM.